We review our computational tools for high-throughput screening by fragment-based docking of large collections of small molecules. Applications to six different enzymes, four proteases, and two protein kinases, are presented. Remarkably, several low-micromolar inhibitors were discovered in each of the high-throughput docking campaigns. Probable reasons for the lack of submicromolar inhibitors are the tiny fraction of chemical space covered by the libraries of available compounds, as well as the approximations in the methods employed for scoring, and the use of a rigid conformation of the target protein.
INTRODUCTION
Among the many significant contributions to computational chemistry and physical chemistry, Martin Karplus has also pioneered the use of molecular fragments to map protein binding sites. His paper with Andrew Miranker on the simultaneous minimization of multiple copies of small and mainly rigid functional groups in the protein force field (MCSS) can be considered as the first fragment-based procedure for drug discovery. 1 Experimental techniques for fragment-based lead identification, such as structure-activity relationship by nuclear magnetic resonance spectroscopy, 2 share the same essential idea as the MCSS approach. Thus the importance of molecular fragments has been recognized and exploited first by computational approaches. 1, 3, 4 More recently, fragment-based drug discovery strategies have been developed using X-ray crystallography, 5 nuclear magnetic resonance spectroscopy, 6 surface plasmon resonance, 7 mass spectrometry, 8, 9 substrate activity screening (where the fragments are substrates later converted into inhibitors [10] [11] [12] ), and tethering. 13, 14 Experimental techniques for fragment-based drug discovery have been discussed in previous reviews which contain a large number of applications. [15] [16] [17] [18] [19] [20] Successful in vitro screening campaigns have been reported for several targets, and a non-exhaustive list includes b-secretase, 7, 15, 21, 22 several protein kinases, [23] [24] [25] [26] [27] DNA gyrase, 28 caspase, 29, 30 anthrax lethal factor, 31 and phosphodiesterase. 32 In this review, we focus on the computational methods for fragment-based docking developed in our research group. We do not discuss in silico approaches developed by others (reviewed in [33] [34] [35] [36] ), but rather describe briefly our computational tools (in Section High-throughput fragment-based docking), and present applications (in Section In silico screening campaigns) to six different enzymes, four proteases and two protein kinases. Notably, it has been possible to identify single-digit micromolar inhibitors for all of the six enzymes by fragment-based docking of large libraries of small molecules. In the Conclusions section we give possible reasons for the difficulties encountered in discovering submicromolar inhibitors by in silico screening of collections of available compounds.
HIGH-THROUGHPUT FRAGMENT-BASED DOCKING
Two essential elements of our in silico screening approach are the fragment-based docking procedure and the scoring based on force field energy 37 with continuum electrostatics solvation. [38] [39] [40] [41] [42] The pipeline for high-throughput docking consists of four consecutive steps ( Figure 1 ): (1) automatic decomposition of each molecule of the library into fragments, 43 (2) fragment docking and ranking of poses, 40, 41 (3) flexible docking of each molecule of the library using the best poses of its fragments as anchors, 44 (4) evaluation of the binding free energy of multiple poses of each compound by the LIECE method (linear interaction energy (LIE) with continuum electrostatics 45 ). The first three steps are performed by computer programs developed in our research group. In the fourth step, CHARMM 46, 47 is used for the energy minimization and finite-difference Poisson calculations.
Decomposition of compounds into fragments
The automatic fragmentation of a molecule into substructures and the selection of the three anchor fragments for docking (see below) are performed by the program DAIM (Decomposition And Identification of Molecules 43 ). The decomposition generates mainly rigid fragments which can be docked very efficiently (as explained in the next subsection). The decomposition of a molecule consists of four steps: ring identification, fragment definition, functional group merging, and completion of the valences. (i) Rings are identified by successively enumerating all neighbors (i.e., directly covalently bound atoms) of every atom, (www.interscience.wiley.com) DOI:10.1002/jmr.981 similar to a breadth-first search. (ii) A fragment is defined as a set of atoms connected by unbreakable bonds. The basic definition of unbreakable bonds includes terminal, double, triple, aromatic bonds, and bonds in rings. Non-rotatable and unbreakable bonds are distinguished in DAIM; a non-rotatable bond is always unbreakable, whereas the reverse is not true (e.g., a double bond is non-rotatable and unbreakable, whereas an amide bond is unbreakable, but can assume more than one conformation). (iii) To form chemically relevant fragments and avoid the generation of many small groups, small functional groups (e.g., -OH, -CH 3 , -CX 3 [where X can be any halogen], -SO 3 , -CHO, -NO 2 , -NH 2 , and -SH) are merged with the fragment they are connected to. Unbreakable bonds and functional groups (points (ii) and (iii), respectively) can be defined by the user. (iv) In the final step, missing atom neighbors are added. An atom will lack a neighbor atom whenever the bond connecting them has been cut. These missing neighbors are replaced by hydrogen atoms to reconstitute the correct valence for every atom. A methyl group is used to fill valences where a hydrogen atom would result in an unwanted additional hydrogen bond direction (e.g., a hydrogen replacing a carbon atom bound to an sp 3 nitrogen).
Docking of anchor fragments
The docking approach implemented in the program SEED determines optimal positions and orientations of small to medium-size molecular fragments in the binding site of a protein. 40, 41 Apolar fragments are docked into hydrophobic regions of the receptor while polar fragments are positioned such that at least one intermolecular hydrogen bond is formed. Each fragment is placed at several thousand different positions with multiple orientations (for a total of in the order of 10 6 poses) and the binding energy is estimated whenever severe clashes are not present (usually about 10 5 poses). The binding energy is the sum of the van der Waals interaction and the electrostatic energy. The latter consists of screened receptorfragment interaction, as well as receptor and fragment desolvations calculated by an efficient numerical implementation of the generalized Born approach. 39 
Flexible docking of library compounds
The flexible-ligand docking approach FFLD uses a genetic algorithm and a very efficient scoring function. 44, 48 The random perturbations (i.e., sampling) in the genetic algorithm affect only the conformation of the ligand; its placement in the binding site is determined by the SEED anchors and a least square fitting method. 49 In this way the position and orientation of the ligand in the binding site are determined by the best binding modes of its fragments previously docked by SEED. On the other hand, the scoring function used in FFLD is based on van der Waals and hydrogen bond terms and does not explicitly include solvation for efficiency reasons. Solvation effects are implicitly accounted for because the poses of the fragments are previously sorted according to force field energy with electrostatic solvation in SEED. FFLD requires three not-necessarily different fragments to place a flexible ligand unambiguously in the binding site, e.g., the fluorobenzene, morpholine, and benzoic acid of compound 2 ( Table 1 ). The automatic definition of the three anchor fragments for each molecule of the library is performed by DAIM using the chemical richness, i.e., the sum of all entries in the DAIM fingerprint. 43 
LIECE binding energy evaluation
The essential idea of linear interaction energy (LIE) models is that the free energy of complex formation can be calculated by considering only the end points of the thermodynamic cycle of Figure 1 . Schematic picture of the pipeline for automatic docking developed in our group. The automatic decomposition of the molecules into rigid fragments is carried out by the program DAIM. 43 The fragments are docked by the program SEED which evaluates the binding free energy including electrostatic solvation effects. 40 The program FFLD 44 is used for flexible ligand docking using positions and orientations of fragment triplets (dashed triangles).
ligand binding, i.e., bound and free states. For this purpose, one usually calculates average values of interaction energies from molecular dynamics simulations of the isolated ligand and the ligand/protein complex. 50, 51 The free energy of binding is approximated by
where E vdW and E elec are the van der Waals and electrostatic interaction energies between the ligand and its environment. The environment is either the solvent (free) or both the protein and solvent (bound). The hi denotes an ensemble average sampled over a molecular dynamics 50 or Monte Carlo 52 trajectory. The coefficient a is determined empirically. 50 Originally, b was fixed to a value of 1/2, as predicted by the linear response approximation. 50 Later studies have shown, however, that improved models for a large variety of systems could be obtained by considering b as a free parameter. 53 Consequently, both coefficients are obtained by a fit of experimentally determined values of DG to the calculated values of E elec and E vdW for a training set of known ligands.
The original LIE method and modifications thereof have been applied to a large number of existing inhibitor/protein datasets. 50, [54] [55] [56] [57] [58] [59] Moreover, LIE-based scorings of ligands were shown to perform better than established scoring functions. 60 Interestingly, recent applications to pharmaceutically relevant enzyme targets have documented the predictive ability and usefulness in lead-discovery projects. As an example, the LIE method with explicit water molecular dynamics sampling was successfully used in the design of a series of inhibitors of the malarial aspartic proteases plasmepsin I and II. 61 Unfortunately, LIE cannot be used for high-throughput docking because of its computational requirements (the currently fastest implementation needs about 6 h for each compound 60 ). Therefore, we have replaced the explicit water molecular dynamics (or Monte Carlo) simulations with a simple energy minimization and combined the LIE method with a rigorous treatment of solvation within the continuum electrostatics approximation, 45 i.e., the numerical solution of the Poisson equation by the finite-difference technique. 62 The LIECE approach, where the last two letters stand for continuum electrostatics, is about two orders of magnitude faster than previous LIE methods and shows a similar precision on the targets tested. In fact, we have observed an error of about 1 kcal/mol for 13 and 29 peptidic inhibitors of b-secretase and HIV-1 protease, respectively. 45 Similar accuracy has been reported for other proteases 63, 64 and five kinases. 65 
Consensus scoring
It has been reported that consensus scoring is generally preferable to the use of a single scoring function. 66 Furthermore, the median rank is more suitable than the average rank in consensus-scoring because the former is less sensitive to outliers. 67 Rank by median consensus scoring was used in the in silico screening against plasmepsin and cathepsin B (Table 1) . For plasmepsin, consensus scoring was preferred to ranking by LIECE because visual inspection of the best LIECE poses revealed several unlikely binding modes. In the case of cathepsin B, the lack of experimental data on inhibitors binding outside the catalytic center was the reason for not using LIECE which requires at least 10-15 binding affinity data points for fitting the 2-3 parameters of the linear model. campaigns on six different enzymes which play a key role in a variety of diseases (Table 1) . Four of these enzymes are proteases of three different classes (aspartic, serine, and cysteine proteases), while the remaining two are a tyrosine kinase and a Ser/Thr kinase. The 2D structures of the most potent inhibitors discovered in the eight high-throughput docking campaigns are shown in Figure 2 .
IN SILICO SCREENING CAMPAIGNS
Alzheimer's disease is the most common neurodegenerative disease and it accounts for the majority of the cases of dementia diagnosed after the age of 60. 68 Amyloid plaques, which are found in the post-mortem brain of Alzheimer's disease patients, 69, 70 consist mainly of fibrillar aggregates of the Ab peptide, a proteolytic cleavage product of the b-amyloid precursor protein (APP). Two enzymes, g-and b-secretase (b-site APP cleaving enzyme) are responsible for the sequential processing of APP. 71 Although it is not clear whether the plaques or oligomeric prefibrillar species are responsible for neuronal loss and dementia, 72 the pepsin-like aspartic protease b-secretase has become one of the major Alzheimer's disease targets. 68, [73] [74] [75] [76] [77] b-Secretase inhibitors have been shown to lower brain Ab after direct intracranial administration 76, 78 or via peripheral administration at relatively high doses in murine models. 75, 76 Moreover, a novel potent tertiary carbinamine inhibitor of b-secretase effectively lowers Ab levels in a non-human primate model. 77 b-Secretase is not an easy target to block. 68, 73, [79] [80] [81] For instance, only a single molecule (1,3,5-trisubstituted benzene) emerged as b-secretase inhibitor from a multimillion compound library submitted to a high-throughput screening campaign. 82 As a proof-of-principle of our in silico screening approach, highthroughput fragment-based docking into the b-secretase active site and LIECE binding free energy evaluation has led to the discovery of three novel series of inhibitors: phenylurea derivatives (e.g., compound 1), 83 triazine derivatives (e.g., compound 2), 84 and a set of five cell-permeable, non-peptide, low-micromolar inhibitors with a different scaffold (D. Huang and A. Caflisch, unpublished results). Among them, the phenylurea derivatives were identified from an initial set of about half a million molecules 83 ( Table 1) . Twelve of the 72 tested compounds inhibit b-secretase in at least one of two different mammalian cell-based assays (EC 50 < 10 mM). It is important to note that for almost all of the 12 compounds, for which an EC 50 value could be measured, the discrepancies between LIECE-predicted affinity and the experimental value is within the LIECE accuracy of about 1 kcal/mol. 45 The triazine derivatives were selected from an initial set of about 300 000. 84 Ten of the 88 tested compounds inhibit b-secretase activity in an enzymatic assay (IC 50 < 100 mM), and four of them are active in a mammalian cell-based assay (EC 50 < 20 mM).
P. falciparum plasmepsin II (malaria)
An estimated 40% of the world's population is a potential victim of malaria, which is responsible for 300-660 million infections annually. 85 Furthermore, there is an urgent need to develop new antimalarial medicines because of the emerging drug resistance. 86 Plasmepsins are pepstatin-like aspartic proteases unique to the malaria parasites (which belong to the genus Plasmodium). They are involved in metabolism and host cell invasion. 87 Ten plasmepsins have been identified in the genome of P. falciparum, the plasmodium species that causes the most fatal form of malaria in human, and four of these 10 are located in the food vacuole, an acidic lysosome-like organelle in which hemoglobin degradation takes place. It has been shown that inhibitors of plasmepsins are fatal to the parasites, 88 which suggests that plasmepsins are pharmaceutically relevant targets. Furthermore, several small-molecule inhibitors of retroviral and human aspartic proteases, namely HIV-protease 89 and renin, 90 are effective and safe medicines, which provides additional support to the relevance of plasmepsins as drug targets.
We used our fragment-based docking procedure to search for inhibitors of plasmepsin II. 63 A total of 4.6 million compounds were first clustered according to 2D structural similarity resulting in about 40 000 molecules which were then used for fragmentbased docking. Docking into the plasmepsin II active site was followed by consensus scoring using four force field-based energy functions. A total of 19 compounds were tested in an enzymatic assay, and three of them showed single-digit micromolar inhibitory activity (Table 1) . 63 One of these three inhibitors is halofantrine (compound 3), an antimalarial drug discovered more than 40 years ago whose mechanism of action is still unknown. To better investigate the binding mode of halofantrine, four 50 ns molecular dynamics simulations with explicit solvent were performed starting from two different poses, one generated by automatic docking and the other by manual fitting with the help of a computer graphics program. The molecular dynamics simulations indicate that the binding mode generated by fragment-based docking is more stable than the one obtained by manual docking although it is not possible to definitively discard either. 63 
West Nile virus NS3 protease (flaviviral infections)
The pathogenic members of the flavivirus family, e.g., West Nile virus and the closely related Dengue virus, are transmitted by mosquito bites. Although an estimated 2.5 billion people are potential victims of encephalitis and other fatal maladies caused by flaviviruses, 91 these diseases have received much less attention than other tropical diseases like avian influenza. Their status as ''neglected'' diseases is in part due to the fact that flaviviruses are widespread mainly in poor countries, and mosquitos can fly only much shorter distances than migratory birds so that they do not represent a threat in developed countries. Recently, the non-structural 3 (NS3) protease has been shown to be responsible for cleavage of the viral polyprotein precursor and to play a pivotal role in the replication of flaviviruses. 92, 93 In fact, site directed mutagenesis focused on the NS3 protease cleavage sites in the polyprotein precursor abolishes viral infectivity. 93 Therefore, the NS3 protease is one of the most promising targets for drug development against flaviviridae infections. In this context it is important to note that two inhibitors of the closely related hepatitis C virus protease are under late-stage clinical development. [94] [95] [96] [97] We have run two in silico screening campaigns to identify inhibitors of the West Nile virus NS3 protease. The first high-throughput docking campaign (Figure 3 , left) was performed on the X-ray structure of the protease 64 while the second campaign ( Figure 3 , right) made use of a snapshot selected along a 1 ns explicit solvent molecular dynamics simulation started from the crystal structure. 98 This snapshot was chosen from a set of 100 as it optimally accommodates three representative molecular fragments: benzene and two functional groups with a positive charge. The former is the most common ring in the known drugs, while the latters were employed because the active site of the NS3 protease has a large amount of hydrogen bond acceptors. Interestingly, the hit rate was high in both campaigns (5 and 40%, Table 1 ). Most importantly, inhibitors 4 and 5 are candidate lead compounds. They occupy only the S1 and S2 pockets of the substrate binding site (Figure 4) , so that additional substituents are expected to improve their affinity and, at the same time, retain good druglike properties as they both have very favorable ligand efficiency (which is defined as the experimentally measured free energy of binding divided by the number of non-hydrogen atoms 99 ). The in silico discovery of compounds 4 and 5 is remarkable because the West Nile virus NS3 protease is a very difficult target. Very few non-peptidic inhibitors have been reported. Moreover, less than 10 molecules emerged as inhibitors (in the micromolar range) from a library of more than one million compounds submitted to a high-throughput in vitro screening campaign. 100 It is interesting to note that compound 5, as well as another inhibitor of the West Nile virus NS3 protease discovered by docking into the molecular dynamics snapshot (the diphenylesther 2 in Reference 98 ), would not have been identified by docking into the X-ray structure, as the S1 pocket in the latter does not accommodate the benzene ring in an energetically favorable way. 98 
Cathepsin B (cancer and rheumatic disorders)
Cathepsin B is capable of endopeptidase, 101 peptidyldipeptidase, 102, 103 and carboxypeptidase activities. 104, 105 Among the cysteine peptidases cathepsin B is unique for the presence of a flexible segment, known as the occluding loop, that can block the primed subsites of the substrate binding cleft. With the occluding loop in the open conformation cathepsin B acts as an endopeptidase, while it acts as an exopeptidase when the loop is closed. Cathepsin B is involved in a number of human disorders. It activates trypsinogen in hereditary pancreatitis, 106 participates in apoptosis, 107 tumor progression and malignancy, 108, 109 and plays an important role in rheumatic diseases. [110] [111] [112] We have targeted the occluding loop of human cathepsin B outside the catalytic center, using high-throughput fragmentbased docking. 113 The aim was to identify inhibitors that would interact with the occluding loop thereby modulating enzyme activity without the help of chemical warheads (i.e., without reactive functional groups that form a covalent bond with residues in the catalytic site but usually also bind unspecifically to other proteins). From a library of about 48 000 compounds, the in silico approach identified compound 6 which fulfills the working hypothesis (Table 1) . This molecule possesses two distinct binding moieties and behaves as a reversible, doubleheaded competitive inhibitor of cathepsin B by excluding synthetic and protein substrates from the active center. The kinetic mechanism of inhibition suggests that the occluding loop is stabilized in its closed conformation, mainly by hydrogen bonds with the inhibitor, thus decreasing endoproteolytic activity of the enzyme. Furthermore, the dioxothiazolidine head of compound 6 sterically hinders binding of the C-terminal residue of substrates resulting in inhibition of the exopeptidase activity of cathepsin B in a physiopathologically relevant pH range. 
EphB4 tyrosine kinase (cancer)
The protein kinase EphB4 (ertythropoietin producing human hepatocellular carcinoma receptor tyrosine kinase B4) is a highly attractive angiogenic target involved in many types of cancer. 114 It seems to be rather recalcitrant to inhibition because, despite its potential therapeutic importance, very few inhibitors have been reported in the literature up to date.
We have developed and applied the ALTA (anchor-based library tailoring) approach to identify ATP-competitive inhibitors of EphB4 115 ( Figure 5 ). ALTA is an automatic fragment-based procedure for focusing libraries of compounds. First, molecular fragments are docked and prioritized (i.e., anchors are selected based on a ranking) according to force field energy which includes continuum electrostatics solvation. 40, 39 Large collections of molecules can then be effectively reduced in size by selecting only the compounds that have one (or more) fragment among the top ranking anchors. In principle, ALTA does not require any information about known inhibitors but in the application to the EphB4 kinase pharmacophore knowledge (hydrogen bonds to the hinge region) was additionally used to efficiently reduce the size of the original library from about 728 000 to 21 418 molecules. Two series of novel EphB4 inhibitors have been identified by ALTA. Compound 7 is a potential candidate for further development because of its low-micromolar affinity and molecular weight of only 337 DA which result in a very favorable ligand efficiency (Table 1) . Moreover, the kinetic characterization of a very similar compound (2 in Table 1 of Reference 115 ) indicates that this series of molecules bind to the ATP-binding site, as predicted by the docking calculations. 115 Recently, single-digit nanomolar affinities have been reached by chemical synthesis of derivatives of compound 7 that were designed on the basis of the binding mode obtained by docking.
116

CDK2 Ser/Thr kinase (cancer)
The human cyclin-dependent kinase 2 (CDK2) is a Ser/Thr kinase that controls cell cycle progression in proliferating eukaryotic cell. [117] [118] [119] The activity of CDK2 is tightly controlled, and fully activated CDK2 is essential for proper S phase progression. Studies have shown that inhibition of CDK2/cyclin A during S phase leads to S phase arrest and apoptosis, which has suggested a pharmacological role for CDK2 inhibitors in the treatment of cancer. 120 A diversity set of 40 375 compounds was used for fragmentbased docking into the X-ray structure of CDK2 (PDB code 1KE5). A threshold in the ratio between van der Waals energy and molecular weight, and the presence of at least one key hydrogen bond were used as filters to discard unfavorable poses. The remaining poses were scored by the two-parameter LIECE model fitted on 73 known CDK2 inhibitors. Thirty compounds were tested in an enzymatic assay, and compound 8 emerged with a single-digit micromolar IC 50 value and a favorable ligand efficiency (0.32 kcal/mol per non-hydrogen atom, Table 1 ). 65 
CONCLUSIONS
Low micromolar inhibitors of four proteases and two protein kinases have been identified by high-throughput screening using fragment-based docking. The catalytic sites of the proteases have very different shape from the ATP-binding sites of the protein kinases. Moreover, the former show a broad range of surface-hydrophilicity ranging from mainly hydrophobic (b-secretase) to a strong electrostatic potential (NS3 protease). It is thus encouraging that docking finds inhibitors for all of them. The six enzymes are involved in key biological processes in humans or human parasites. Therefore, they are relevant drug targets: b-secretase in Alzheimer's disease, cathepsin B in cancer and rheumatic disorders, EphB4 tyrosine kinase in cancer-related angiogenesis, CDK2 Ser/Thr kinase in several types of cancer, plasmepsin II in malaria, and NS3 protease in infections caused by flaviviruses, in particular West Nile virus and Dengue virus. Recently, a series of 50 derivatives of the inhibitor 7 of the EphB4 tyrosine kinase have been synthesized. These 50 compounds were designed using the binding mode obtained by automatic docking. Notably, six of these compounds are active in the submicromolar range and one of them has an IC 50 value of about 5 nM. 116 It is likely that medicinal chemistry optimization of all of the inhibitors presented in this review article (i.e., discovered by high-throughput docking) might yield (low) nanomolar inhibitors but it is very difficult to predict in advance the eventual improvement in potency. 115 The first step is the automatic decomposition 43 of a library of compounds (orange rectangle) to obtain the pool of fragments. Afterwards, fragments selected based on the binding site features are docked 40 and ranked according to their binding energy. 41 Poses for molecules that contain at least one of the top-ranking fragments are then generated by flexible-ligand docking.
One essential component of our scoring approach is the use of a force field energy supplemented by the evaluation of electrostatic solvation effects. The latter are calculated by models of aqueous solvent based on the continuum dielectric approximation. For fragment docking, the generalized Born approximation is used for evaluating the electrostatic component of the binding free energy which includes screened electrostatic interaction, and protein and fragment desolvation terms. 40, 41 The finite-difference Poisson equation is employed to calculate electrostatic solvation effects for the poses of the compounds obtained by flexible ligand docking. The poses are then usually ranked by the LIECE approach. 45, 65 The two main outcomes of our in silico screening campaigns on six different enzymes are that the hit rate is rather high (between 3 and 40%) and the most potent inhibitors have low micromolar affinity and favorable ligand efficiency (Table 1 ). It is difficult to compare hit rates reported in different studies due to differences in the libraries employed for screening and in the affinity thresholds adopted for the definition of hits. Yet, our hit rates compare favorably with those reported for experimental highthroughput screening (0.01-0.1%) and fragment-based screening (0.1-1%) techniques. Moreover, in silico screening involves much smaller time, consumables, and labor costs than in vitro screening.
It was not possible to identify submicromolar inhibitors in the eight high-throughput docking campaigns (for six different enzymes), probably because one or more of the three following reasons. First, the libraries of available compounds cover a very small fraction of the potential druglike molecules. In fact, it has been estimated that the number of potential fragments with up to 11 heavy atoms (under constraints due to chemical stability and synthetic feasibility) is on the order of 10 7 , 121 while the number of druglike molecules with less than 30 heavy atoms is larger than 10 60 . 122 Furthermore, it is likely that the coverage of chemical space is very heterogeneous in the libraries of compounds that are available. A recent analysis of commercially available compounds suggests that that the chemical space is skewed mainly toward ligands of G-protein coupled receptors (10.6% of the compounds in a database of about 1 million small molecules resemble known ligands of these receptors) with fewer kinase-like ligands (4.2%) and an even smaller amount of compounds resembling protease inhibitors (2.3%). 123 Note also that an 80-nM ATP-competitive inhibitor of casein kinase II has been identified by high-throughput docking of a subset of the Novartis collection of compounds (about 400 000 molecules in 2003, which are not in the public domain). 124 Second, there are significant sources of errors in both the force field and continuum dielectric model used to approximate solvation effects. As an example polarization effects are neglected in force fields based on fixed partial charges. A recent extension of the LIECE model has emphasized the importance of quantum mechanics to capture these effects, in particular for sets of inhibitors with significant differences in the number of formal charges. 125 Third, all docking studies presented in this review were performed with a rigid protein. The rigid-protein approximation, which is required for efficiency reasons, dramatically restricts the number of favorable poses and results in false negatives. As an example, two small-molecule inhibitors of the NS3 protease have been identified by docking into a molecular dynamics snapshot, which would not have been possible by using the X-ray structure. 98 In conclusion, we have reviewed our computational tools for fragment-based library docking and presented applications to six different enzymes. The scoring of poses based on force field energy with implicit solvation has shown robustness in identifying low micromolar inhibitors. Therefore, for target proteins of known three-dimensional structure, the efficiency and high hit rate of our fragment-based docking approach makes it a cost-effective alternative to experimental screening techniques, in particular in the lead identification phase of the drug discovery process.
